Cell&Co BioServices
Cell&Co BioServices (now Cryoport Systems France) provides GMP-compliant biobanking, temperature-controlled storage, clinical sample management, central laboratory, and pharmaceutical logistics services to pharmaceutical, biotech, animal-health, and clinical research clients across Europe.
- Company typePrivate
- Founded2013
- HeadquartersClermont-ferrand, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cell&Co BioServices does
Cell&Co BioServices, now operating as Cryoport Systems France following its 2022 acquisition by NASDAQ-listed Cryoport (CYRX), is a France-based specialty services company focused on the secure management and storage of biological samples and pharmaceutical products. Founded in 2013 in Pont-du-Château and headquartered in Clermont-Ferrand, the company operates two GMP-grade sites totaling 2,140 m² that provide temperature-controlled storage (-20°C, -80°C, cryogenic), clinical trial sample management, central laboratory services, biobanking, and pharmaceutical activities including EU Batch certification, importation, secondary packaging, QP release, and drug return/destruction. Cell&Co also designs and produces custom sample collection kits compliant with GCP and operates proprietary innovations such as the Biotracker IT sample-tracking platform and a tamper-evident cryobox sealing system.
The company serves a regulated enterprise customer base spanning pharmaceutical and biotechnology manufacturers (Enterome, ONXEO, Scancell, IPSEN), animal-health companies (Royal Canin), non-governmental research organizations (DNDI, IFCT), and multicenter academic hospital networks — including a documented engagement requiring centralized sample repatriation from more than 70 French hospitals. Its competitive position rests on an unusually dense stack of regulatory authorizations (ANSM MIA, Cell Therapy Product Conservation, Human Tissue Conservation, Starting Materials for Pharma Use) combined with ISO 9001:2015 and ISO 20387:2018 certifications and compliance with GMP, GDP, GCP, GCLP, EU GMP Annex 11, and FDA 21 CFR Part 11; CIR accreditation (2022-2026) further allows clients to claim a 30% French research tax credit on Cell&Co invoices.
The business model is B2B enterprise services delivered through direct field sales and dedicated account management, supported by an integrated client portal and participation in industry conferences (France Bioproduction, AFCROs Clinical Research Day, Innovative Biologics & CMC Challenges). Revenue is generated through a mix of recurring subscription-like storage contracts (GMP biorepository, biobanking) and project-based professional services (clinical sample management, central laboratory, bespoke R&D, pharmaceutical services), with pricing conducted on a contact basis and customized per client specification. Since April 2022, the company has been a wholly-owned subsidiary of Cryoport Systems, retaining its name and on-the-ground management under founding CEO Florent Belon and Chairman Sofien Dessolin, while accessing Cryoport's 33-location global temperature-controlled supply chain network.
Cell&Co BioServices firmographics
Firmographics- Name
- Cell&Co BioServices
- Legal name
- Cell&Co BioServices
- Website
- https://cell-and-co.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cell&Co BioServices (now Cryoport Systems France) provides GMP-compliant biobanking, temperature-controlled storage, clinical sample management, central laboratory, and pharmaceutical logistics services to pharmaceutical, biotech, animal-health, and clinical research clients across Europe.
- Ownership category
- akta.pro rank
Cell&Co BioServices industry classification
Industry- Product category
- Biobanking and Biological Sample Management Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
- akta.pro secondary industries
- GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ), Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO)
Keywords
Where Cell&Co BioServices is headquartered
LocationHeadquarters
- HQ city
- Clermont-ferrand
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Cell&Co BioServices business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain
Revenue model
- Biobanking Services: Biocollections management, secure storage, and biobanking services for biological samples
- GMP Biorepository: Storage of raw materials and products in pharmaceutical environment for secure bioproduction
- Clinical Sample Management (CSM): Management of clinical trial samples including logistics, preparation, and analysis
- Central Laboratory Services: Laboratory services for biomedical research including sample preparation and analysis
- Pharmaceutical Services: Drug packaging, labeling, QP services, drug return and destruction, and pharmaceutical product management
- R&D Studies: Custom R&D studies including stability studies and bespoke research projects
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Cell&Co BioServices product offering
Product offeringCore offering
Cell&Co BioServices provides specialized B2B services for the secure management of biological and pharmaceutical samples across their full lifecycle. Core offerings include GMP-compliant biobanking and biorepository storage, centralized laboratory analysis, clinical trial sample management, pharmaceutical product handling (packaging, labeling, QP certification, return/destruction), pre-analytical preparation (PBMC isolation, aliquoting, extractions), and bespoke R&D studies. All services are delivered from two ANSM-authorized, ISO-certified sites in France with 24/7 monitored cold chain infrastructure.
Product overview
Cell&Co BioServices (now Cryoport Systems France) is a specialized services company offering an integrated portfolio of biological sample management and pharmaceutical logistics solutions. The core offerings include: Biobank for biological sample storage, GMP Biorepository (Biorepository BPF) for pharmaceutical-grade storage, and Central Laboratory for biomedical research. These are complemented by pre-analytical services (PBMC isolation, aliquoting, extractions), sample collection kit design/production, emergency storage, biobank consulting, bespoke R&D studies, and pharmaceutical services (GMP material management, drug packaging/labeling, QP services, drug return/destruction). The company also developed proprietary innovations including a tamper-evident sealing system for cryoboxes. Services span the full sample lifecycle from collection through storage to disposal, with emphasis on quality, traceability, and regulatory compliance.
Differentiator
Problem solved
Functional benefit
Products and services
- Biobank (Biobanque)
Quantifiable outcome
- 30% CIR tax credit reimbursement for clients
- +2 more outcomes
Companies that use Cell&Co BioServices
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Cell&Co BioServices technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cell&Co BioServices partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CryoportcoreCryoport acquired Cell&Co BioServices on April 18, 2022. This acquisition integrates Cell&Co into Cryoport's global temperature-controlled supply chain platform. Cell&Co maintains its name and operational identity while benefiting from Cryoport's international network of 33 strategic locations across Americas, EMEA, and APAC. The integration supports Cell&Co's pharmaceutical activities and European expansion including new sites under construction.
Scale indicators4 records
Recent moves9 records
Expansion highlights5 records
Cell&Co BioServices competitors and assessment
Company assessmentDirect peers
- LabConnect: LabConnect provides central laboratory, sample management, and biorepository services for clinical trials worldwide. Its focus on clinical trial support and integrated lab services makes it a direct specialist peer in the same niche as Cell&Co's central lab and clinical sample management business.
- Q² Solutions: Q² Solutions is a clinical trial laboratory services organization providing central lab, biospecimen management, and biorepository services to pharma and biotech sponsors. Its trial-support sample logistics and central lab capabilities overlap directly with Cell&Co's clinical sample management and central lab offerings.
- Azenta Life Sciences (formerly Brooks Life Sciences): Azenta operates one of the largest global biobanking, sample management, and cold-chain storage networks, directly competing with Cell&Co for pharmaceutical and biotech storage contracts. Its biorepository services, integrated IT tracking, and central lab capabilities closely mirror Cell&Co's core offering.
Broad incumbents
- IQVIA: IQVIA is a global CRO with central laboratory services and clinical trial sample management at global scale. It competes for the same enterprise pharma and biotech sample logistics contracts as Cell&Co, with a much broader portfolio of services.
- Eurofins Scientific: Eurofins is a global bioanalytical laboratory group with central lab, biobanking, and clinical trial sample management services. Its European footprint and central lab capabilities make it a broad incumbent against which Cell&Co's specialized French offering is benchmarked.
- Charles River Laboratories: Charles River is a global CRO/CDMO with broad biopharma services including biobanking, cell banking, and biostorage capabilities. While not solely focused on biobanking, it competes for the same biopharma sample management RFPs and offers adjacent regulatory and quality services.
- SGS Life Sciences: SGS provides clinical research, bioanalytical, and biopharma services including central lab and sample management. Its global scale and pharmaceutical testing portfolio position it as a broader incumbent competing for similar enterprise pharma contracts.
Others
- Cryoport Systems: Cryoport is the parent company that acquired Cell&Co in April 2022 and now operates it as Cryoport Systems France. While not a peer in the competitive sense, Cryoport's broader temperature-controlled supply chain solutions and global 33-site network directly extend Cell&Co's service portfolio.
Emerging players
- Vineti: Vineti offers a cell therapy orchestration platform and supporting supply chain services for advanced therapies. As cell and gene therapy demand grows, its narrower focus overlaps with Cell&Co's cell therapy product conservation authorization and broader pharma services.
- TrakCel: TrakCel provides cell orchestration and supply chain tracking software for cell and gene therapies. While primarily software-led, it competes in the broader ecosystem of cell therapy compliance and traceability that Cell&Co's ANSM-authorized storage and Biotracker system also serves.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Cell&Co BioServices social profiles
Digital presenceCell&Co BioServices compliance and trust
Trust signalCompliance15 records
Cell&Co BioServices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cell&Co BioServices leadership team
Management profileNumber of profiles
Profiles14 records
Cell&Co BioServices funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cell&Co BioServices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cell&Co BioServices
What does Cell&Co BioServices do?
Cell&Co BioServices provides specialized B2B services for the secure management of biological and pharmaceutical samples across their full lifecycle. Core offerings include GMP-compliant biobanking and biorepository storage, centralized laboratory analysis, clinical trial sample management, pharmaceutical product handling (packaging, labeling, QP certification, return/destruction), pre-analytical preparation (PBMC isolation, aliquoting, extractions), and bespoke R&D studies. All services are delivered from two ANSM-authorized, ISO-certified sites in France with 24/7 monitored cold chain infrastructure.
Is Cell&Co BioServices a public or private company?
Cell&Co BioServices is a private company. It is classified as corporate owned and is currently operating.
When was Cell&Co BioServices founded?
Cell&Co BioServices was founded in 2013. It employs 11 to 50 people.
Where is Cell&Co BioServices based?
Cell&Co BioServices is headquartered in Clermont-ferrand, France, in the Europe region.
How does Cell&Co BioServices make money?
Six revenue lines are on record. Biobanking Services are the primary driver. The others are GMP Biorepository, clinical Sample Management (CSM), central Laboratory Services, pharmaceutical Services and R&D Studies.
Who are Cell&Co BioServices's main competitors?
Direct peers on record are LabConnect, Q² Solutions and Azenta Life Sciences (formerly Brooks Life Sciences). Broad incumbents are IQVIA, Eurofins Scientific, Charles River Laboratories and SGS Life Sciences. Cryoport Systems is listed as an others. Emerging players are Vineti and TrakCel.
Does Cell&Co BioServices have an API?
No public API is recorded for Cell&Co BioServices.
What industry is Cell&Co BioServices in?
Cell&Co BioServices's product category is Biobanking and Biological Sample Management Services. Its primary akta.pro industry code is HLAGAEAI, Sample Logistics, Biorepository & IVD Kit Management (Trial Support), with a secondary code of HLAGAGAL, GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification). Its NAICS code is 541714 and its SIC code is 8731.